High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: A phase II and parmacodynamic study

Annals of Oncology

Volumn 9, Issue 2, 1998, Pages 173-180

  Rowinsky, E K ^a,b   Baker, S D ^a,b   Burks, K ^a   O'Reilly, S ^a   Donehower, R C ^a   Grochow, L B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

Colorectal cancer; Granulocyte colony stimulating factor; Pharmacokinetics; Phase II; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROPYRIMIDINE; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; FEMALE; HUMAN; MALE; MULTIDRUG RESISTANCE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; PYRIMIDINES; TOPOTECAN; TREATMENT FAILURE;

EID: 0031940425     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008266630701     Document Type: Article

References (33)

1. Slichenmyer WJ, Rowinsky EK, Donehower RC et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85: 271-91.
2. Kingsbury WD, Boehm JC, Jakas DR et al. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: Inhibition of topoisomerase I and antitumor activity. J Med Chem 1991; 34: 98-107.
3. Hertzberg RP, Caranfa MJ, Holden KG et al. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989; 32: 715-7.
4. Kantajarian HM, Beran M, Ellis A et al. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed leukemia. Blood 1993; 81: 1146-51.
5. Rowinsky EK, Adjei A, Donehower RC et al. A phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994; 12: 2193-2203.
6. Rowinsky EK, Kaufmann SH, Baker SH et al. A phase I and pharmacological study of topotecan in patients with refractory acute leukemia. Clin Cancer Res 1996; 2: 1921-30.
7. Carmichael J, Ozols RF. Topotecan, an active new antineoplastic agent: Review and current status. Exp Opin Invest Drugs 1997; 6: 593-608.
8. SmithKline Beecham Pharmaceuticals. Topotecan, NSC 609669 Investigator Brochure. King of Prussia, PA. June 1994.
9. Creemers GJ, Gerrits CJH, Schellens JHM et al. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 1996; 14: 2540-5.
10. Creemers GJ, Wanders J, Gamucci T et al. Topotecan in colorectal cancer: A phase II study of the EORTC Early Clinical Trials Group. Ann Oncol 1995; 6: 844-6.
11. Sugarman SM, Ajani JA, Daugherty K et al. A phase II trial of topotecan for treatment of advanced measurable colorectal cancer. Proc Am Soc Clin Oncol 1994; 12: 686 (Abstr).
12. Hochster H, Ibrahim J, Liebes L et al. Phase II study of 21-day topotecan continuous infusion for metastatic colorectal cancer (ECOG 4923). Proc Am Soc Clin Oncol 1997; 16: 290 (Abstr).
13. Shimada Y, Yoshina M, Wakui A et al. Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909-13.
14. Pitot HC, Wender D, O'Connell MJ et al. A phase II trial of CPT-11 (irnotecan) in patients with metastatic colorectal carcinoma: A North Central Cancer Center Treatment Group (NCCTG) study. Proc Am Soc Clin Oncol 1994; 13: 197.
15. Conti JA, Kemeny NE, Saltz LB et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 709-15.
16. Rothenberg ML, Eckardt JR, Kuhn JG et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128-35.
17. Rougier P, Bugat R, Douillard JY et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-60.
18. Hendricks CB, Rowinsky EK, Grochow LB et al. Effect of P-glycoprotein expression on accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analog. Cancer Res 1992; 52: 2268-78.
19. Chen AY, Yu C, Potmesil M, Wall ME et al. Camptothecin overcomes mdr1-mediated resistance in human KB carcinoma cells. Cancer Res 1991; 51: 6039-44.
20. Tsuruo T, Matsuzaki T, Matsushita M et al. Antitumor activity of CPT-11, a new derivative of camptotecin, against pleotropic drug resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988; 21: 71-4.
21. Mattern MR, Hofmann GA, Polsky RM et al. In vitro and in vivo effects of clinically important campothecin analogues in multidrug-resistant cells. Oncol Res 1993; 5: 467-74.
22. Rowinsky EK, Grochow LB. Sartorious SE et al. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996; 14: 1224-35.
23. Haas NB, LaCreta FP, Walczak J et al. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 1994; 54: 1220-6.
24. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles, Ca. Boimed Sim Res 1997.
25. Rowinsky E, Grochow L, Hendricks C et al. Phase I and pharmacologic study of topotecan (SK&F 104864): A novel topoisomerase I inhibitor. J Clin Oncol 1992; 10: 647-56.
26. van Warmerdam LJC, Verweij J, Schellens JHM et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for five days every three weeks. Cancer Chemother Pharmacol 1995; 35: 237-45.
27. Saltz L, Sirott M, Young C et al. Phase I clinical and pharmacology study of topotecan given daily for five consecutive days to patients with advanced solid tumors, with, attempt at dose intensification using recombinant granulocyte colony-stimulating factor. J Natl Cancer Inst 1993; 85: 1499-1507.
28. Hochster H, Liebes L, Speyer J et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well tolerated regimen. J Clin Oncol 1994; 12: 553-9.
29. Zomboni WC, Houghton PJ, Johnson RK. Probenecid alters topotecan (TPT) systemic and renal disposition. Clin Pharmacol Ther 1996; 61: 145.
30. Potmesil M. Camptothecins: From bench research to hospital wards. Cancer Res 1994; 54: 1431-9.
31. Blaney SM, Cole DE, Godwin K et al. Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol 1995; 36: 121-4.
32. Baker SD, Heideman RL, Crom WR et al. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with recurrent acute leukemia. Cancer Chemother Pharmacol 1996; 37: 195-202.
33. Rothenberg ML, Moore MJ, Cripps MC et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 343-53.